LABORATORIO REIG JOFRE (ES:RJF) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Reig Jofre, a pharmaceutical company listed on the Spanish stock exchange, has reported a robust financial performance for Q3 2024, with a 7% rise in revenues and a 10% increase in EBITDA, driven by international market growth and investments in industrial capacity. The company’s operating profit surged by 22%, supported by the success of its Specialty Pharmacare and Pharmaceutical Technologies divisions, alongside strategic investments totaling €13.6 million. Despite inflationary pressures, the company maintained a stable debt/EBITDA ratio and anticipates continued profitability through its global expansion and product optimization strategies.
For further insights into ES:RJF stock, check out TipRanks’ Stock Analysis page.